Washington’s Medicaid program will start paying for a friendly AI-powered robot called ElliQ to keep seniors company and help them stay independent and healthy at home.
CSL Behring disclosed a "temporary global stockout" of its gene therapy for hemophilia B that it says could delay treatment for some patients.
The FDA will now consider granting its regenerative medicine designations to experimental therapies even if they are on clinical hold, a shift in operating procedures that could help smaller biotechs developing cell and gene therapies ...
Pfizer said a combination of two of its prostate cancer drugs — Talzenna and Xtandi — succeeded in a Phase 3 study and that it plans to ask regulators for earlier use of Talzenna, a PARP inhibitor ...
The FDA unveiled long-awaited draft guidance on how biopharma companies can validate new approaches for toxicology and other early-phase safety studies, potentially reducing the animal testing that's long been used to assess the risks of ...
Collegium Pharmaceutical is beefing up its portfolio in ADHD with the acquisition of Corium's FDA-approved drug Azstarys.
In San Francisco a few weeks ago, I caught up with Nworah Ayogu, partner at Thrive Capital. Thrive had recently announced that it raised a $10 billion+ fund.
ACIP is being broken up. No it’s not.
After selling her previous biotech for over $1 billion in 2019, it didn’t take long before Clarissa Desjardins decided to try it again.
Lawmakers on a bipartisan House panel conveyed they are ready to tackle China’s growing dominance in the development of new medicines and the ingredients that underpin the generic drug market.
Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a similar margin as Mounjaro achieved in its pivotal diabetes study.
Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly lower margin than Mounjaro achieved in its pivotal diabetes study.
AstraZeneca has added more details on how it will use its $15 billion budget to expand in China — and the UK pharma is betting on cell therapy.
The FDA approved a high-dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, giving its go-ahead about two months faster than normal thanks to a voucher received from the commissioner's program.
Basecamp Research, an AI-focused biotech startup partnered with Microsoft and Nvidia, is setting off on its most ambitious trek yet: To collect genetic sequences of more than a trillion proteins in the next two years.
Always be in the clinic — those are the "ABCs" of biotech, drug development veteran Briggs Morrison tells Endpoints News. And that's precisely where Morrison's Crossbow Therapeutics has been for the past few quarters with its ...